Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer
Umberto Malapelle(Federico II University Hospital), Carlos Camps(Universitat de València), Rafael Sirera(Antwerp University Hospital), Silvia Calabuig‐Fariñas(Hospital General Universitario De Valencia), Eloísa Jantus‐Lewintre(Hospital General Universitario De Valencia), Pasquale Pisapia(University of Naples Federico II), Ana Blasco(Hospital General Universitario De Valencia), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Pablo Reclusa(University of Antwerp)
Cited by 171
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642